Phase
Condition
Bronchitis
Copd (Chronic Obstructive Pulmonary Disease)
Chronic Obstructive Lung Disease
Treatment
N/AClinical Study ID
Ages 40-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Inclusion Criteria
Capability to provide written informed consent
Age ≥ 40 years and ≤ 85 years
FEV1/FVC ratio (post bronchodilator) < 70%
FEV1 (post bronchodilator) < 65%
Presence of chronic cough and sputum production defined as the following:
Presence of chronic cough and sputum will be defined by responses to the first two questions on the SGRQ (see Appendix A). Subjects who respond positively to both question 1 (cough) and question 2 (sputum) on the SGRQ as either "several days per week" or "almost every day" will be eligible
Current or former smoker with lifetime cigarette consumption of at least 10 pack-years
Negative serum pregnancy test at the baseline visit if patient is a pre-menopausal female (menopause defined as absence of a menstrual cycle in the last 12 months)
Must be fluent in speaking the English language
Exclusion Criteria
Not fully recovered for at least 30 days from a COPD exacerbation characterized by typical symptoms and treated with antibiotics or prednisone
Known allergy or sensitivity to NAC or albuterol
Any patient with unstable cardiac disease
Any patient with a documented history of uncompensated congestive heart failure in the last 2 years
Clinical diagnosis of asthma, bronchiectasis, cystic fibrosis, or severe alpha-1 antitrypsin deficiency
Active lung cancer or history of lung cancer if it has been less than 2 years since lung resection or other treatment. If history of lung cancer, must have no evidence of recurrence in the 2 years preceding the baseline visit.
Undergoing active treatment for malignancy except for hormonal therapy (i.e. prostate cancer, breast cancer) or non-metastatic skin cancer and are not symptomatic
Chronic kidney disease with an estimated GFR of < 30 ml/min. GFR will be estimated using the Modification of Diet in Renal Disease (MDRD) formula
History of cirrhosis with evidence of portal hypertension (ascites, chronic edema)
Participation in a pulmonary rehabilitation program or completion within past 6 weeks
Prisoners or institutionalized patients
Participation in another study involving an investigational product within 30 days of the baseline visit
Pregnant or breast-feeding patients.
Use of guaifenesin in the last 30 days
Currently on long acting nitrates for angina or heart failure
Abnormalities in screening blood work defined as:
WBC < 3.0 or > 15.0 K/cmm
Hemoglobin < 9.0 or > 17.0 gm/dl
Platelets < 75 or > 400 K/cmm
ALT > 3 times the upper limit of normal
INR > 1.5 unless on warfarin therapy o Any concomitant condition that might endanger the patient through participation in the study or interfere with study procedures, as assessed by the investigator
Study Design
Connect with a study center
Minneapolis VA Health Care System
Minneapolis, Minnesota 55417
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.